The cell and gene therapy clinical trial services market size has grown rapidly in recent years. It will grow from $3.44 billion in 2023 to $3.79 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The growth observed during the historic period can be attributed to several factors, including the heightened prevalence of chronic diseases, growing demand for effective treatments targeting rare genetic disorders, increased government funding allocated to research in regenerative medicine, enhanced understanding of molecular mechanisms associated with various diseases, and heightened awareness regarding the potential benefits of personalized medicine.
The cell and gene therapy clinical trial services market size is expected to see rapid growth in the next few years. It will grow to $5.64 billion in 2028 at a compound annual growth rate (CAGR) of 10.4%. The anticipated growth in the forecast period can be attributed to several factors, including the increasing global incidence of genetic and autoimmune diseases, rising funding from both public and private sectors for gene therapy research, growing adoption of novel technologies, and an increase in the number of genetic defects identified. Major trends expected during this period include the adoption of Artificial Intelligence (AI) and machine learning, the integration of personalized medicine, advancements in technology, and the development of gene therapies.
The increasing prevalence of genetic diseases is expected to drive the expansion of the cell and gene therapy clinical trial services market in the future. Genetic diseases result from variations in an individual's DNA or genetic makeup and are becoming more common due to factors such as increased accessibility to genetic testing, occurrences of genetic mutations, and the prevalence of consanguineous marriages. Cell and gene therapy clinical trial services play a crucial role in addressing the growing incidence of genetic diseases by fostering the development of innovative treatments, customizing therapies for individual patients, accelerating the translation of research into clinical applications, and broadening the treatment options available to patients with genetic disorders. For instance, according to the Cystic Fibrosis (CF) Foundation's July 2022 report, there has been a notable increase in the number of individuals diagnosed with cystic fibrosis, affecting nearly 40,000 children and adults in the United States alone, and over 105,000 people worldwide. Consequently, the rising prevalence of genetic diseases is a key driver behind the growth of the cell and gene therapy clinical trial services market.
Leading companies in the cell and gene therapy clinical trial services market are concentrating their efforts on introducing advanced technology, including customer relationship management (CRM) system technology, to enhance operational efficiency and gain a competitive advantage. CRM systems utilized by cell and gene therapy clinical trial services streamline and manage interactions with trial participants, healthcare providers, and other stakeholders throughout the clinical trial process. For instance, in April 2023, AmerisourceBergen Corporation unveiled the Cell and Gene Therapy (CGT) Integration Hub, a platform designed to enhance connectivity and streamline processes across the cell and gene therapy treatment pathway. Supported by AmerisourceBergen's CRM system, this platform aims to simplify care coordination by providing physicians and patient services teams with better visibility throughout the therapy development and delivery process. The CGT Integration Hub includes features such as expedited benefits investigation, real-time status tracking, and proactive alerts, all aimed at simplifying care coordination and improving the overall patient and provider experience in delivering cell and gene therapies.
In January 2024, Kyowa Kirin Co. Ltd. acquired Orchard Therapeutics Limited to strengthen its focus on addressing unmet medical needs in genetic and severe diseases by leveraging Orchard's expertise in developing and commercializing gene therapies for rare diseases. Orchard Therapeutics Limited, a UK-based biotechnology company, is dedicated to researching, developing, and commercializing gene therapies for rare diseases.
Major companies operating in the cell and gene therapy clinical trial services market are Thermo Fisher Scientific Inc., Sharp Services LLC, IQVIA, Laboratory Corporation of America Holdings, ICON plc, Syneos Health Inc., Catalent Pharma Solutions Inc., Charles River Laboratories International Inc., Parexel International Corporation, PRA Health Sciences Inc., Covance Inc., Medpace Holdings Inc., BioClinica Inc., Precision Medicine Group LLC, Worldwide Clinical Trials LLC, Clinigen Group plc, Evidera Inc., Advarra LLC, Veristat LLC, Clinipace Inc., Celonic AG, Cromsource Inc., Novotech Pty Ltd., MedSource Holdings Inc., Frontage Laboratories Inc.
North America was the largest region in the cell and gene therapy clinical trial services market in 2023. It is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy clinical trial services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell and gene therapy clinical trial services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Cell and gene therapy clinical trial services are specialized offerings provided by contract research organizations (CROs) or clinical trial management firms to support the design, implementation, and oversight of clinical trials for cell and gene therapies. These services encompass various aspects such as protocol design, patient recruitment, regulatory compliance, and data management, ensuring precision, efficacy, and adherence to rigorous standards throughout the trial process.
The primary types of cell and gene therapy clinical trial services include clinical trial design and planning, supply chain and logistics management, regulatory affairs and compliance, data management and biostatistics, site management and monitoring, among others. Clinical trial design and planning entail the development and organization of trial protocols, determining the objectives and methodologies of the trial. Various types of therapies, including gene therapy, cell therapy, and gene-modified cell therapy, are utilized for a range of indications such as oncology, hematology, metabolic disorders, infectious diseases, neurology, cardiovascular diseases, musculoskeletal disorders, among others. These services cater to a diverse range of end-users, including pharmaceutical and biotechnology companies, contract research organizations, academic and research institutions, among others.
The cell and gene therapy clinical trial services market research report is one of a series of new reports that provides cell and gene therapy clinical trial services market statistics, including cell and gene therapy clinical trial services industry global market size, regional shares, competitors with a cell and gene therapy clinical trial services market share, detailed cell and gene therapy clinical trial services market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy clinical trial services industry. This cell and gene therapy clinical trial services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cell and gene therapy clinical trial services market includes revenues earned by providing services, such as regulatory pathways navigation, logistics management, patient retention strategy management, and biomarker analysis services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The cell and gene therapy clinical trial services market size is expected to see rapid growth in the next few years. It will grow to $5.64 billion in 2028 at a compound annual growth rate (CAGR) of 10.4%. The anticipated growth in the forecast period can be attributed to several factors, including the increasing global incidence of genetic and autoimmune diseases, rising funding from both public and private sectors for gene therapy research, growing adoption of novel technologies, and an increase in the number of genetic defects identified. Major trends expected during this period include the adoption of Artificial Intelligence (AI) and machine learning, the integration of personalized medicine, advancements in technology, and the development of gene therapies.
The increasing prevalence of genetic diseases is expected to drive the expansion of the cell and gene therapy clinical trial services market in the future. Genetic diseases result from variations in an individual's DNA or genetic makeup and are becoming more common due to factors such as increased accessibility to genetic testing, occurrences of genetic mutations, and the prevalence of consanguineous marriages. Cell and gene therapy clinical trial services play a crucial role in addressing the growing incidence of genetic diseases by fostering the development of innovative treatments, customizing therapies for individual patients, accelerating the translation of research into clinical applications, and broadening the treatment options available to patients with genetic disorders. For instance, according to the Cystic Fibrosis (CF) Foundation's July 2022 report, there has been a notable increase in the number of individuals diagnosed with cystic fibrosis, affecting nearly 40,000 children and adults in the United States alone, and over 105,000 people worldwide. Consequently, the rising prevalence of genetic diseases is a key driver behind the growth of the cell and gene therapy clinical trial services market.
Leading companies in the cell and gene therapy clinical trial services market are concentrating their efforts on introducing advanced technology, including customer relationship management (CRM) system technology, to enhance operational efficiency and gain a competitive advantage. CRM systems utilized by cell and gene therapy clinical trial services streamline and manage interactions with trial participants, healthcare providers, and other stakeholders throughout the clinical trial process. For instance, in April 2023, AmerisourceBergen Corporation unveiled the Cell and Gene Therapy (CGT) Integration Hub, a platform designed to enhance connectivity and streamline processes across the cell and gene therapy treatment pathway. Supported by AmerisourceBergen's CRM system, this platform aims to simplify care coordination by providing physicians and patient services teams with better visibility throughout the therapy development and delivery process. The CGT Integration Hub includes features such as expedited benefits investigation, real-time status tracking, and proactive alerts, all aimed at simplifying care coordination and improving the overall patient and provider experience in delivering cell and gene therapies.
In January 2024, Kyowa Kirin Co. Ltd. acquired Orchard Therapeutics Limited to strengthen its focus on addressing unmet medical needs in genetic and severe diseases by leveraging Orchard's expertise in developing and commercializing gene therapies for rare diseases. Orchard Therapeutics Limited, a UK-based biotechnology company, is dedicated to researching, developing, and commercializing gene therapies for rare diseases.
Major companies operating in the cell and gene therapy clinical trial services market are Thermo Fisher Scientific Inc., Sharp Services LLC, IQVIA, Laboratory Corporation of America Holdings, ICON plc, Syneos Health Inc., Catalent Pharma Solutions Inc., Charles River Laboratories International Inc., Parexel International Corporation, PRA Health Sciences Inc., Covance Inc., Medpace Holdings Inc., BioClinica Inc., Precision Medicine Group LLC, Worldwide Clinical Trials LLC, Clinigen Group plc, Evidera Inc., Advarra LLC, Veristat LLC, Clinipace Inc., Celonic AG, Cromsource Inc., Novotech Pty Ltd., MedSource Holdings Inc., Frontage Laboratories Inc.
North America was the largest region in the cell and gene therapy clinical trial services market in 2023. It is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy clinical trial services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell and gene therapy clinical trial services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Cell and gene therapy clinical trial services are specialized offerings provided by contract research organizations (CROs) or clinical trial management firms to support the design, implementation, and oversight of clinical trials for cell and gene therapies. These services encompass various aspects such as protocol design, patient recruitment, regulatory compliance, and data management, ensuring precision, efficacy, and adherence to rigorous standards throughout the trial process.
The primary types of cell and gene therapy clinical trial services include clinical trial design and planning, supply chain and logistics management, regulatory affairs and compliance, data management and biostatistics, site management and monitoring, among others. Clinical trial design and planning entail the development and organization of trial protocols, determining the objectives and methodologies of the trial. Various types of therapies, including gene therapy, cell therapy, and gene-modified cell therapy, are utilized for a range of indications such as oncology, hematology, metabolic disorders, infectious diseases, neurology, cardiovascular diseases, musculoskeletal disorders, among others. These services cater to a diverse range of end-users, including pharmaceutical and biotechnology companies, contract research organizations, academic and research institutions, among others.
The cell and gene therapy clinical trial services market research report is one of a series of new reports that provides cell and gene therapy clinical trial services market statistics, including cell and gene therapy clinical trial services industry global market size, regional shares, competitors with a cell and gene therapy clinical trial services market share, detailed cell and gene therapy clinical trial services market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy clinical trial services industry. This cell and gene therapy clinical trial services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cell and gene therapy clinical trial services market includes revenues earned by providing services, such as regulatory pathways navigation, logistics management, patient retention strategy management, and biomarker analysis services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Cell and Gene Therapy Clinical Trial Services Market Characteristics3. Cell and Gene Therapy Clinical Trial Services Market Trends and Strategies32. Global Cell and Gene Therapy Clinical Trial Services Market Competitive Benchmarking33. Global Cell and Gene Therapy Clinical Trial Services Market Competitive Dashboard34. Key Mergers and Acquisitions in the Cell and Gene Therapy Clinical Trial Services Market
4. Cell and Gene Therapy Clinical Trial Services Market - Macro Economic Scenario
5. Global Cell and Gene Therapy Clinical Trial Services Market Size and Growth
6. Cell and Gene Therapy Clinical Trial Services Market Segmentation
7. Cell and Gene Therapy Clinical Trial Services Market Regional and Country Analysis
8. Asia-Pacific Cell and Gene Therapy Clinical Trial Services Market
9. China Cell and Gene Therapy Clinical Trial Services Market
10. India Cell and Gene Therapy Clinical Trial Services Market
11. Japan Cell and Gene Therapy Clinical Trial Services Market
12. Australia Cell and Gene Therapy Clinical Trial Services Market
13. Indonesia Cell and Gene Therapy Clinical Trial Services Market
14. South Korea Cell and Gene Therapy Clinical Trial Services Market
15. Western Europe Cell and Gene Therapy Clinical Trial Services Market
16. UK Cell and Gene Therapy Clinical Trial Services Market
17. Germany Cell and Gene Therapy Clinical Trial Services Market
18. France Cell and Gene Therapy Clinical Trial Services Market
19. Italy Cell and Gene Therapy Clinical Trial Services Market
20. Spain Cell and Gene Therapy Clinical Trial Services Market
21. Eastern Europe Cell and Gene Therapy Clinical Trial Services Market
22. Russia Cell and Gene Therapy Clinical Trial Services Market
23. North America Cell and Gene Therapy Clinical Trial Services Market
24. USA Cell and Gene Therapy Clinical Trial Services Market
25. Canada Cell and Gene Therapy Clinical Trial Services Market
26. South America Cell and Gene Therapy Clinical Trial Services Market
27. Brazil Cell and Gene Therapy Clinical Trial Services Market
28. Middle East Cell and Gene Therapy Clinical Trial Services Market
29. Africa Cell and Gene Therapy Clinical Trial Services Market
30. Cell and Gene Therapy Clinical Trial Services Market Competitive Landscape and Company Profiles
31. Cell and Gene Therapy Clinical Trial Services Market Other Major and Innovative Companies
35. Cell and Gene Therapy Clinical Trial Services Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Cell And Gene Therapy Clinical Trial Services Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on cell and gene therapy clinical trial services market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cell and gene therapy clinical trial services? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cell and gene therapy clinical trial services market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Service: Clinical Trial Design And Planning; Supply And Logistic Services; Regulatory Affairs And Compliance; Data Management And Biostatics; Site Management And Monitoring; Other Services2) By Therapy Type: Gene Therapy; Cell Therapy; Gene Modified Cell Therapy
3) By Indication: Oncology; Hematology; Metabolic Disorders; Infectious Diseases; Neurology; Cardiovascular Diseases; Musculoskeletal Disorders; Other Indications
4) By End-Use: Pharmaceutical And Biotechnology Companies; Contract Research Organizations; Academic And Research Institutes; Other End-Users
Key Companies Mentioned: Thermo Fisher Scientific Inc.; Sharp Services LLC; IQVIA; Laboratory Corporation of America Holdings; ICON plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Thermo Fisher Scientific Inc.
- Sharp Services LLC
- IQVIA
- Laboratory Corporation of America Holdings
- ICON plc
- Syneos Health Inc.
- Catalent Pharma Solutions Inc.
- Charles River Laboratories International Inc.
- Parexel International Corporation
- PRA Health Sciences Inc.
- Covance Inc.
- Medpace Holdings Inc.
- BioClinica Inc.
- Precision Medicine Group LLC
- Worldwide Clinical Trials LLC
- Clinigen Group plc
- Evidera Inc.
- Advarra LLC
- Veristat LLC
- Clinipace Inc.
- Celonic AG
- Cromsource Inc.
- Novotech Pty Ltd.
- MedSource Holdings Inc.
- Frontage Laboratories Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | July 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 3.79 Billion |
| Forecasted Market Value ( USD | $ 5.64 Billion |
| Compound Annual Growth Rate | 10.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
